These findings demonstrate the essential importance of the prohibitin/E2F pathway in estrogen antagonist-induced growth suppression, and identify prohibitin and Brg1/Brm as potential novel targets for the design of improved anti-breast cancer therapy (Wang et al. 2004). Here, SMARCA2 is linked to breast carcinoma.